Using an electronic medical records database to identify non-traditional cardiovascular risk factors in nonalcoholic fatty liver disease

American Journal of Gastroenterology

Volumn 111, Issue 5, 2016, Pages 671-676

  Corey, Kathleen E ^a,b   Kartoun, Uri ^a,b   Zheng, Hui ^a,b   Chung, Raymond T ^a,b   Shaw, Stanley Y ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; SODIUM;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SODIUM BLOOD LEVEL; AGED; ALGORITHM; CARDIOVASCULAR DISEASES; COMPLICATION; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; MIDDLE AGED; PREVALENCE; STATISTICAL MODEL;

ADULT; AGED; ALGORITHMS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTORS;

EID: 84959542329     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.44     Document Type: Article

References (37)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95
2. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9
3. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects wiThelevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602
4. Bhala N, Angulo P, van Der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-16
5. Rafi q N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8
6. Adams LA, Lymp JF St, Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21
7. Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology 2015; 274: 693-701
8. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-50
9. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21
10. Treeprasertsuk S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 945-50
11. Marchesini G, Ronchi M, Forlani G, et al. Cardiovascular disease in cirrhosis - A point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999; 94: 655-62
12. Albillos A, Rossi I, Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 1995; 268: G459-G464
13. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32: 141-56
14. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007; 24: 1-6
15. Corey K, Kartoun U, Zheng H, et al. Development and validation of an algorithm to identify nonalcoholic fatty liver disease in the electronic medical record. Dig Dis Sci 2015, 1-7
16. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifi es liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54
17. Kamath PS, Kim WR. Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805
18. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients wiThend-stage liver disease. Hepatology 2001; 33: 464-70
19. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-8
20. Telem DA, Schiano T, Goldstone R, et al. Factors that predict outcome of abdominal operations in patients with advanced cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 451-7
21. Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011; 9: 254-9
22. Bhangui P, Laurent A, Amathieu R, et al. Assessment of risk for non-hepatic surgery in cirrhotic patients. J Hepatol 2012; 57: 874-84
23. Singal AG, Rahimi RS, Clark C, et al. An automated model using electronic medical record data identifi es patients with cirrhosis at high risk for readmission. Clin Gastroenterol Hepatol 2013; 11: 1335-41
24. Younossi ZM, Henry L, Stepanova M. A new comorbidity model for predicting mortality in patients with cirrhosis: does it work? Gastroenterology 2014; 146: 19-24
25. Sharma P, Schaubel DE, Goodrich NP, et al. Serum sodium and survival benefit of liver transplantation. Liver Transplant 2015; 21: 308-13
26. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32-9
27. De Vito R, Alisi A, Masotti A, et al. Markers of activated Inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med 2012; 30: 49-56
28. Sookoian S, Castano GO, Burgueno AL, et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010; 209: 585-91
29. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452-5
30. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma Inflammatory biomarkers independently of visceral fat in men. Obesity 2008; 16: 1394-9
31. Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences. J Th romb Haemost 2011; 9: 1713-23
32. Targher G, Chonchol M, Miele L, et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Th romb Hemost 2009; 35: 277-87
33. Barrett-Connor E, Khaw K. Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation 1984; 69: 1065-9
34. Lloyd-Jones DM, Nam BH, D?Agostino RB Sr., et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and off spring. J Am Med Assoc 2004; 291: 2204-11
35. Andresdottir MB, Sigurdsson G, Sigvaldason H, et al. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J 2002; 23: 1655-63
36. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99: 1165-72
37. Wong VW, Chim AM, Wong GL, et al. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transplant 2007; 13: 1228-35